表紙
市場調查報告書
商品編碼
1040457

第一型糖尿病的全球市場(2021年∼2027年)

Type 1 Diabetes Market 2021-2027

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球第一型糖尿病的市場規模在預測期間內預計將以7.8%的年複合成長率成長。帶動這個市場的主要原因有能夠進行早期檢測的診斷能力提高而促使的研究數量增加。市場機遇包括隨著技術進步對非侵入性監測設備的需求、不斷上升的醫療保健成本以及政府為遏製糖尿病高患病率所做的努力和財政支持。

本報告提供全球第一型糖尿病市場調查,提供市場概要,市場的推動因素與阻礙因素分析,COVID-19的影響,市場機會,胰島素類似物·藥物類別·設備·各地區的市場分析,主要企業的簡介等系統性資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢

第3章 競爭情形

  • 主要企業分析
    • Abbott Laboratories
    • AstraZeneca PLC
    • Bayer AG
    • Eli-Lilly and Co.
    • F-Hoffman La Roche Ltd.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近的開發
  • 主要策略分析
  • COVID-19對主要企業的影響

第4章 市場決策要素

  • 促進因素
  • 阻礙因素
  • 市場機會

第5章 市場細分化

  • 第一型糖尿病的全球市場:各胰島素類似物場
    • 速效型
    • 長時間作用型
    • 預混合料
  • 第一型糖尿病的全球市場:各類藥物
    • 胰島素
    • 非胰島素
  • 第一型糖尿病的全球市場:各設備
    • 胰島素幫浦
    • 胰島素筆針
    • 血糖值計
    • 其他

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他地區

第7章 企業簡介

  • Abbott Laboratories
  • AstraZeneca, PLC
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Co.
  • Astellas Pharma Inc.
  • Becton, Dickinson and Co.
  • Boehringer Ingelheim International GmbH.
  • Bristol-Myers Squibb
  • Dexcom, Inc.
  • GlaxoSmithKline Plc
  • Medtronic, PLC
  • Merck & Co., Inc.
  • Novartis International AG
  • Novo-Nordisk A/S
  • Sanofi S.A.
  • Takeda Pharmaceutical, Ltd.
  • Tandem Diabetes Care, Inc.
  • ViaCyte, Inc.
  • Welldoc, Inc.
目錄
Product Code: OMR2024008

Global Type 1 Diabetes Treatment Market Size, Share &Trends Analysis Report By Insulin Analog (Rapid-Acting, Long-Acting, and Premix), By Drug Class (Insulin and Non-Insulin), By Devices (Insulin Pumps, Insulin Pen, Blood Glucose Meters, and Others) Forecast, 2021-2027

The global type 1 diabetes treatment market is growing at a CAGR of 7.8% during the forecast period (2021-2027) The market is set to display impressive growth during the forecast period with some key trends emerging, such as the increased number of researches driven by improved diagnostic capabilities ensuring early detection. The type-1 diabetes treatment market is focused on the production and refurbishment of rapid-acting drugs and devices for the treatment of diabetes within tight time constraints. It also depends on the level of inventory management practices of OEM and MRO clients

The need for non-invasive monitoring devices with technological advancements, rising healthcare expenditure, and government initiatives and funding to control the high prevalence of diabetes are some of the opportunities for the market players. For instance, according to the IDF, the total diabetes-related healthcare expenditure was $294,558 million which is expected to reach $309,419 million by 2045.

The global type 1 diabetes treatment market suffered a downfall during the COVID-19 crisis as most of the economic activities were halted during Q1 and Q2 2020. Most major revenue-generating market players showed a decline in their sales due to less manufacturing of insulins in the major economies. The patients suffering from diabetes are at higher risk of COVID-19 and hence the market is expected to grow and have a "W" shaped recovery in the forecast period

The market is segmented based on insulin analog, drug class, and devices. Based on the insulin analog segment, the market is segmented into rapid-acting, long-acting, and premix. Based on the drug class segment, the market is segmented into insulin and non-insulin. The insulin segment was estimated to have a major share in marker in 2020. Further, based on the devices segment, the market is segmented into insulin pumps, insulin pens, blood glucose meters, and others.

Geographically type-1 diabetes treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific is the fastest-growing market for type 1 diabetes. Innovative manufacturing, which was once a stronghold of the US and a few European economies such as France, Italy, and Germany, is set to expand to emerging economies, with next-generation largescale manufacturing centers to be planned predominantly in the Asia-Pacific region. The growth in the number of type-1 diabetes patients with the rising number of populations, increase in the number of patients with high blood pressure, and technological advancements in the Asian economies of Japan, South Korea, Taiwan, and China, which involve the highest degree of innovations, is set to increase the market demand. Europe was also estimated to have a significant share in the market. In the UK, 1 in every 430-530 people under the age of 19 have Type 1 diabetes.

The key players of the market include Merck &Co., Inc., Novo-Nordisk A/S, Sanofi S.A., Medtronic, PLC., AstraZeneca, PLC, F. Hoffmann-La Roche Ltd, and Becton, Dickinson, and Co, among others. These key manufacturers are adopting various strategies such as new product launches and approvals, mergers and acquisitions, partnerships and collaborations, and many others to thrive in a competitive environment. For instance, In September 2019, Vertex announced the acquisition of Semma Therapeutics for $950 million for developing curative cell-based treatments for type 1 diabetes.

Research Methodology

The market study of the global type 1 diabetes treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market

Whitepapers, research papers, and news blogs

Company websites and their product catalog

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Type 1 diabetes treatment Market Research and Analysis by Insulin Analog

Global Type 1 diabetes treatment Market Research and Analysis by Drug Class

Global Type 1 diabetes treatment Market Research and Analysis by Devices

The Report Covers

Comprehensive research methodology of the global type 1 diabetes treatment market

This report also includes a detailed and extensive market overview with key analyst insights

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations

Analysis of regional regulations and other government policies impacting the global type 1 diabetes treatment market

Insights about market determinants that are stimulating the global type 1 diabetes treatment market

Detailed and extensive market segments with the regional distribution of forecasted revenues

Extensive profiles and recent developments of market players

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Type 1 Diabetes Treatment Industry
  • Recovery Scenario of Global Type 1 Diabetes Treatment Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Abbott Laboratories
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
    • 3.1.2. AstraZeneca PLC
      • 3.1.2.1. Overview
      • 3.1.2.2. Financial Analysis
      • 3.1.2.3. SWOT Analysis
      • 3.1.2.4. Recent Developments
    • 3.1.3. Bayer AG
      • 3.1.3.1. Overview
      • 3.1.3.2. Financial Analysis
      • 3.1.3.3. SWOT Analysis
      • 3.1.3.4. Recent Developments
    • 3.1.4. Eli-Lilly and Co.
      • 3.1.4.1. Overview
      • 3.1.4.2. Financial Analysis
      • 3.1.4.3. SWOT Analysis
      • 3.1.4.4. Recent Developments
    • 3.1.5. F-Hoffman La Roche Ltd.
    • 3.1.6. Overview
    • 3.1.7. Financial Analysis
    • 3.1.8. SWOT Analysis
    • 3.1.9. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Type 1 Diabetes Treatment Market by Insulin Analog
    • 5.1.1. Rapid-Acting
    • 5.1.2. Long-Acting
    • 5.1.3. Premix
  • 5.2. Global Type 1 DiabetesTreatment Market by Drug Class
    • 5.2.1. Insulin
    • 5.2.2. Non-Insulin
  • 5.3. Global Type 1 DiabetesTreatment Market by Devices
    • 5.3.1. Insulin Pumps
    • 5.3.2. Insulin Pen
    • 5.3.3. Blood Glucose Meters
    • 5.3.4. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. AstraZeneca, PLC
  • 7.3. F. Hoffmann-La Roche Ltd
  • 7.4. Eli Lilly and Co.
  • 7.5. Astellas Pharma Inc.
  • 7.6. Becton, Dickinson and Co.
  • 7.7. Boehringer Ingelheim International GmbH.
  • 7.8. Bristol-Myers Squibb
  • 7.9. Dexcom, Inc.
  • 7.10. GlaxoSmithKline Plc
  • 7.11. Medtronic, PLC
  • 7.12. Merck & Co., Inc.
  • 7.13. Novartis International AG
  • 7.14. Novo-Nordisk A/S
  • 7.15. Sanofi S.A.
  • 7.16. Takeda Pharmaceutical, Ltd.
  • 7.17. Tandem Diabetes Care, Inc.
  • 7.18. ViaCyte, Inc.
  • 7.19. Welldoc, Inc.

LIST OF TABLES

1. GLOBAL TYPE 1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLIONS)

  • 2. GLOBAL TYPE 1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSIS BY INSULIN ANALOG, 2020-2027 ($ MILLION)

3. GLOBAL RAPID-ACTING INSULIN ANALOG FOR TYPE-1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLIONS)

4. GLOBAL LONG-ACTING INSULIN ANALOG FOR TYPE-1 DIABETESTREATMENTMARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLIONS)

5. GLOBAL PREMIX INSULIN ANALOG FOR TYPE-1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLIONS)

6. GLOBAL TYPE 1 DIABETES TREATMENT MARKET AND RESEARCH ANALYSIS BY DRUG CLASSBY REGION, 2020-2027 ($ MILLIONS)

7. GLOBAL INSULIN FOR TYPE 1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLIONS)

8. GLOBAL NON-INSULINFOR TYPE 1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLIONS)

9. GLOBAL TYPE 1 DIABETESTREATMENT MARKET RESEARCH AND ANALYSIS BY DEVICES, 2020-2027 ($ MILLIONS)

10. GLOBAL INSULIN PUMPS FOR TYPE 1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSISBY REGION, 2017-20223 ($ MILLIONS)

11. GLOBAL INSULIN PEN FOR TYPE 1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027($ MILLIONS)

12. GLOBAL BLOOD GLUCOSE MONITORSFOR TYPE 1 DIABETESTREATMENT MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLIONS)

13. GLOBAL OTHERSDEVICES FOR TYPE 1 DIABETESTREATMENTMARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLIONS)

14. NORTH AMERICANTYPE 1 DIABETESTREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($MILLIONS)

15. NORTH AMERICANTYPE 1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSIS BY INSULIN ANALOG, 2020-2027 ($MILLIONS)

16. NORTH AMERICANTYPE 1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($MILLIONS)

17. NORTH AMERICANTYPE 1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSIS BY DEVICES, 2020-2027 ($MILLIONS)

18. EUROPEANTYPE 1 DIABETESTREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($MILLIONS)

19. EUROPEANTYPE 1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSIS BY INSULIN ANALOG, 2020-2027 ($MILLIONS)

20. EUROPEANTYPE 1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($MILLIONS)

21. EUROPEANTYPE 1 DIABETESTREATMENT MARKET RESEARCH AND ANALYSIS BY DEVICES, 2020-2027 ($MILLIONS)

22. ASIA-PACIFICTYPE 1 DIABETESTREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($MILLIONS)

23. ASIA-PACIFICTYPE 1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSIS BY INSULIN ANALOG, 2020-2027 ($MILLIONS)

24. ASIA-PACIFICTYPE 1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($MILLIONS)

25. ASIA-PACIFICTYPE 1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSIS BY DEVICES, 2020-2027 ($MILLIONS)

26. REST OF THE WORLDTYPE 1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSIS BY DEVICES, 2020-2027 ($MILLIONS)

27. REST OF THE WORLDTYPE 1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSIS BY INSULIN ANALOG, 2020-2027 ($MILLIONS)

28. REST OF THE WORLDTYPE 1 DIABETES TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($MILLIONS)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL TYPE 1 DIABETESTREATMENT MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL TYPE 1 DIABETESTREATMENT MARKET BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL TYPE 1 DIABETESTREATMENT MARKET, 2020-2027 (%)

4. GLOBAL TYPE 1 DIABETESTREATMENT MARKET SHARE BY INSULIN ANALOG,2020 VS 2027, (IN %)

5. GLOBAL TYPE 1 DIABETES TREATMENT MARKET SHARE BY DRUG CLASS,2020VS 2027, (IN %)

6. GLOBAL TYPE 1 DIABETES TREATMENT MARKET SHARE BY DEVICES,2020VS 2027, (IN %)

7. GLOBAL TYPE 1 DIABETES TREATMENT MARKET SHARE BY GEOGRAPHY,2020VS 2027, (IN %)

  • 8. GLOBAL RAPID-ACTING INSULIN ANALOG FOR TYPE-1 DIABETES TREATMENT MARKET SHARE BY REGION, 2020 VS 2027(%)

9. GLOBAL LONG-ACTING INSULIN ANALOG FOR TYPE-1 DIABETES TREATMENT MARKET SHARE BY REGION, 2020 VS 2027(%))

  • 10. GLOBAL PREMIX INSULIN ANALOG FOR TYPE-1 DIABETES TREATMENT MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 11. GLOBAL INSULIN FOR TYPE 1 DIABETES TREATMENT MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 12. GLOBAL NON-INSULIN FOR TYPE 1 DIABETESTREATMENTMARKET SHARE BY REGION, 2020 VS 2027(%)
  • 13. GLOBAL INSULIN PUMPS FOR TYPE 1 DIABETES TREATMENT MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 14. GLOBAL INSULIN PEN FOR TYPE 1 DIABETESTREATMENTMARKET SHARE BY REGION, 2020 VS 2027(%)
  • 15. GLOBAL BLOOD GLUCOSE METERS FOR TYPE 1 DIABETES TREATMENT MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 16. GLOBAL OTHER DEVICES FOR TYPE 1 DIABETES TREATMENT MARKET SHARE BY REGION, 2020 VS 2027(%)

17. US TYPE 1 DIABETES TREATMENT MARKET SIZE, 2020-2027 ($MILLIONS)

18. CANADA TYPE 1 DIABETES TREATMENT MARKET SIZE, 2020-2027 ($MILLIONS)

19. UK TYPE 1 DIABETES TREATMENT MARKET SIZE, 2020-2027 ($MILLIONS)

20. FRANCE TYPE 1 DIABETES TREATMENT MARKET SIZE, 2020-2027 ($MILLIONS)

21. GERMANY TYPE 1 DIABETES TREATMENT MARKET SIZE, 2020-2027 ($MILLIONS)

22. ITALY TYPE 1 DIABETESTREATMENT MARKET SIZE, 2020-2027 ($MILLIONS)

23. SPAIN TYPE 1 DIABETES TREATMENT MARKET SIZE, 2020-2027 ($MILLIONS)

24. ROE TYPE 1 DIABETES TREATMENT MARKET SIZE, 2020-2027 ($MILLIONS)

25. INDIA TYPE 1 DIABETES TREATMENT MARKET SIZE, 2020-2027 ($MILLIONS)

26. CHINA TYPE 1 DIABETES TREATMENT MARKET SIZE, 2020-2027 ($MILLIONS)

27. JAPAN TYPE 1 DIABETES TREATMENT MARKET SIZE, 2020-2027 ($MILLIONS)

28. SOUTH KOREA TYPE 1 DIABETES TREATMENT MARKET SIZE, 2020-2027 ($MILLIONS)

29. ROAPAC TYPE 1 DIABETES TREATMENT MARKET SIZE, 2020-2027 ($MILLIONS)

30. REST OF THE WORLD TYPE 1 DIABETES TREATMENT MARKET SIZE, 2020-2027 ($MILLIONS)